Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting

-  Poster presentations on BMB-101 will focus on 5-HT_2C functional selectivity and Phase 1 clinical data  -

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, is proud to announce two upcoming presentations at the American Epilepsy Society 2024 Annual Meeting in Los Angeles, December 6-10, 2024.

Read more at globenewswire.com